CN103374540A - Corynebacterium glutamicum and application thereof - Google Patents
Corynebacterium glutamicum and application thereof Download PDFInfo
- Publication number
- CN103374540A CN103374540A CN2013103519909A CN201310351990A CN103374540A CN 103374540 A CN103374540 A CN 103374540A CN 2013103519909 A CN2013103519909 A CN 2013103519909A CN 201310351990 A CN201310351990 A CN 201310351990A CN 103374540 A CN103374540 A CN 103374540A
- Authority
- CN
- China
- Prior art keywords
- corynebacterium glutamicum
- glutaminate
- cgmcc
- deposit number
- mhz
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000186226 Corynebacterium glutamicum Species 0.000 title claims abstract description 66
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims abstract description 68
- 238000000855 fermentation Methods 0.000 claims abstract description 21
- 230000004151 fermentation Effects 0.000 claims abstract description 21
- 238000004519 manufacturing process Methods 0.000 claims abstract description 15
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 claims abstract description 12
- 238000012216 screening Methods 0.000 claims abstract description 9
- 239000002609 medium Substances 0.000 claims description 17
- QTENRWWVYAAPBI-YCRXJPFRSA-N streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O QTENRWWVYAAPBI-YCRXJPFRSA-N 0.000 claims description 15
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims description 12
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 claims description 12
- 244000005700 microbiome Species 0.000 claims description 11
- 239000001963 growth medium Substances 0.000 claims description 9
- 238000011218 seed culture Methods 0.000 claims description 9
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 8
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 8
- 229910019142 PO4 Inorganic materials 0.000 claims description 8
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 8
- 240000008042 Zea mays Species 0.000 claims description 8
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 8
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 8
- 235000005822 corn Nutrition 0.000 claims description 8
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 8
- 239000008103 glucose Substances 0.000 claims description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 8
- 239000010452 phosphate Substances 0.000 claims description 8
- 239000011591 potassium Substances 0.000 claims description 8
- 229910052700 potassium Inorganic materials 0.000 claims description 8
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 6
- 239000004202 carbamide Substances 0.000 claims description 6
- 235000019270 ammonium chloride Nutrition 0.000 claims description 4
- 229910000019 calcium carbonate Inorganic materials 0.000 claims description 4
- 239000011790 ferrous sulphate Substances 0.000 claims description 4
- 235000003891 ferrous sulphate Nutrition 0.000 claims description 4
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 claims description 4
- 229910000359 iron(II) sulfate Inorganic materials 0.000 claims description 4
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 claims description 4
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims description 4
- 229960001763 zinc sulfate Drugs 0.000 claims description 4
- 229910000368 zinc sulfate Inorganic materials 0.000 claims description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 abstract description 8
- 238000003786 synthesis reaction Methods 0.000 abstract description 7
- 229930193140 Neomycin Natural products 0.000 abstract description 6
- 229960004927 neomycin Drugs 0.000 abstract description 6
- 230000015572 biosynthetic process Effects 0.000 abstract description 4
- 229960005322 streptomycin Drugs 0.000 abstract description 4
- 238000004321 preservation Methods 0.000 abstract description 3
- 230000000813 microbial effect Effects 0.000 abstract description 2
- 229930182816 L-glutamine Natural products 0.000 abstract 5
- 230000001580 bacterial effect Effects 0.000 description 23
- 241000894006 Bacteria Species 0.000 description 12
- 229940126575 aminoglycoside Drugs 0.000 description 8
- 238000000034 method Methods 0.000 description 7
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 3
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 3
- VZUNGTLZRAYYDE-UHFFFAOYSA-N N-methyl-N'-nitro-N-nitrosoguanidine Chemical compound O=NN(C)C(=N)N[N+]([O-])=O VZUNGTLZRAYYDE-UHFFFAOYSA-N 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229960002989 glutamic acid Drugs 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 238000009776 industrial production Methods 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 241000589565 Flavobacterium Species 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 229920001807 Urea-formaldehyde Polymers 0.000 description 2
- 229930003756 Vitamin B7 Natural products 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 201000005917 gastric ulcer Diseases 0.000 description 2
- 230000002070 germicidal effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 235000011912 vitamin B7 Nutrition 0.000 description 2
- 239000011735 vitamin B7 Substances 0.000 description 2
- NWNOWCGAHDFNFJ-RUCXOUQFSA-N (2s)-2,5-bis(azanyl)-5-oxidanylidene-pentanoic acid Chemical compound OC(=O)[C@@H](N)CCC(N)=O.OC(=O)[C@@H](N)CCC(N)=O NWNOWCGAHDFNFJ-RUCXOUQFSA-N 0.000 description 1
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- MSWZFWKMSRAUBD-IVMDWMLBSA-N 2-amino-2-deoxy-D-glucopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
- NLJVXZFCYKWXLH-DXTIXLATSA-N 3-[(3r,6s,9s,12s,15s,17s,20s,22r,25s,28s)-20-(2-amino-2-oxoethyl)-9-(3-aminopropyl)-3,22,25-tribenzyl-15-[(4-hydroxyphenyl)methyl]-6-(2-methylpropyl)-2,5,8,11,14,18,21,24,27-nonaoxo-12-propan-2-yl-1,4,7,10,13,16,19,23,26-nonazabicyclo[26.3.0]hentriacontan Chemical compound C([C@H]1C(=O)N[C@H](C(=O)N[C@@H](CCCN)C(=O)N[C@H](C(N[C@H](CC=2C=CC=CC=2)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(O)=O)N1)=O)CC(C)C)C(C)C)C1=CC=C(O)C=C1 NLJVXZFCYKWXLH-DXTIXLATSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000186312 Brevibacterium sp. Species 0.000 description 1
- 241000186249 Corynebacterium sp. Species 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 241000191936 Micrococcus sp. Species 0.000 description 1
- 241000187708 Micromonospora Species 0.000 description 1
- 102000001621 Mucoproteins Human genes 0.000 description 1
- 108010093825 Mucoproteins Proteins 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 241001655322 Streptomycetales Species 0.000 description 1
- 108010021006 Tyrothricin Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- -1 VitB1 Chemical compound 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000000266 alpha-aminoacyl group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000386 athletic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- 230000003570 biosynthesizing effect Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000003925 brain function Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000013066 combination product Substances 0.000 description 1
- 229940127555 combination product Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 229950001902 dimevamide Drugs 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 238000012262 fermentative production Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 229960002442 glucosamine Drugs 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000002337 glycosamines Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000010189 intracellular transport Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 231100000350 mutagenesis Toxicity 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000004708 ribosome subunit Anatomy 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229960003281 tyrothricin Drugs 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The invention relates to the microbial field, and discloses corynebacterium glutamicum strains and application thereof. A corynebacterium glutamicum MHZ-0510 strain has a preservation number CGMCC No.7939; a corynebacterium glutamicum MHZ-0511 strain has a preservation number CGMCC No.7940; the two strains have significantly improved ability of fermentation for generating L-glutamine, compared with that of the original strain of wild type of corynebacterium glutamicum B498, and can be widely applied to fermentation production of L-glutamine. The corynebacterium glutamicum strains involved in the invention are obtained by screening aminoglycoside antibiotics, such as streptomycin and neomycin, have resistance to the aminoglycoside antibiotics including streptomycin and neomycin, and have improved ability to synthesis of L-glutamine, thus increasing the yield of L-glutamine. Therefore, aminoglycoside antibiotics can be widely applied to screen of L-glutamine.
Description
Technical field
The present invention relates to microorganism field, relate to specifically Corynebacterium glutamicum and application thereof.
Background technology
L-glutaminate, formal name used at school are 2-amino-5-carboxyl valeramide, are the acid amides of L-glutamic acid.The L-glutaminate molecular formula is C
10H
20N
4O
6, molecular weight is 292.289, structural formula is
L-glutaminate is one of amino acid the abundantest in the body fluid, accounts for 61% of human body total free aminoacids, is the conditionally essential amino acid that human body is the most general, can not lack.L-glutaminate major storage in the human body is in skeletal muscle, and its concentration will be higher than 30 times of internal milieu, just discharges when needing.L-glutaminate has multiple effect, as can strengthen immunologic function, safeguard acid base equilibrium, increase cell volume, the strengthen muscle cell protein is synthetic, participate in the biosynthesizing of the mucoprotein constituent glucosamine of alimentary canal mucous membrane, thereby promote the reparation of mucosal epithelium tissue, help the elimination of ulcer focus.Simultaneously, L-glutaminate can promote the brain metabolism by hemato encephalic barrier, improves the brain function, and the same with L-glutamic acid is the important nutrition agent of brain metabolism.In addition, L-glutaminate also can be used for treating the fatigue recovery after athletic movement syndrome and highly intensive labour or the work, rebuilds immunity system, is conducive to treatment and supports liver function, reduces the side effect of radiation and chemotherapy in the cancer therapy.So glutamine is not only a kind of important biochemical reagents, also be a kind of extremely rising new drug simultaneously.
L-glutaminate is widely used abroad as medicinal amino acid, and Germany is because it is written into pharmacopeia aspect the diseases such as stomach ulcer, gastritis, duodenal ulcer good curative effect being arranged as medicine; In Japan, L-glutaminate has obtained general use as stomach and intestine class medicine and strong sirloin product; It is also quite extensive to the use of L-glutaminate that the U.S. is used for the treatment of the health care medicine of the diseases such as stomach ulcer; China is also because its excellent characteristics in the recovery of patients after surgery, and is widely used in medical industry.
The production method of L-glutaminate mainly contains chemical synthesis, enzymic synthesis and fermentation method.Wherein the chemical synthesis reactions steps is various.Although and the enzymic synthesis reactions steps relatively simply but wherein essential reactant Triphosaden (ATP) is expensive, simultaneously enzymatic reaction substrate NH
4+, byproduct adenosine diphosphate (ADP) (ADP) all obviously suppresses the generation of L-glutaminate, therefore can not satisfy the needs of large-scale industrial production.And fermentation method has the advantages such as raw material sources are extensive, production cost is low, quality product is controlled, product is single, therefore is present the most frequently used L-Gln production method.
L-glutaminate output height is inseparable with the microbial strains of adopting, L-glutaminate is produced bacterial classification mainly from glutamate producing bacterium, such as excellent bacillus (Corynebacterium sp.), tyrothricin (Brevibacterium sp.), micrococci (Micrococcus sp.).In addition, also have non-glutamic acid to produce bacterium, such as some variation bacterial classifications of flavobacterium (Flavobacterium rigense).Wherein Corynebacterium glutamicum is one of bacterial classification commonly used in the L-glutaminate fermentation, but its L-glutaminate output is not high, far can not satisfy the large-scale industrial production of L-glutaminate.
Summary of the invention
In view of this, the object of the present invention is to provide Corynebacterium glutamicum and application thereof, to improve the output of L-glutaminate, satisfy the large-scale industrial production of L-glutaminate.
For achieving the above object, the present invention adopts following technical scheme:
The invention provides a kind of Corynebacterium glutamicum, be deposited in China Committee for Culture Collection of Microorganisms common micro-organisms center, deposit number is CGMCC No.7939.
It is the application of Corynebacterium glutamicum in producing L-glutaminate of CGMCC No.7939 that the present invention provides deposit number simultaneously.
The present invention also provides a kind of Corynebacterium glutamicum, is deposited in China Committee for Culture Collection of Microorganisms common micro-organisms center, and deposit number is CGMCC No.7940.
It is the application of Corynebacterium glutamicum in producing L-glutaminate of CGMCC No.7940 that the present invention provides deposit number simultaneously.
The present invention also provides a kind of production method of L-glutaminate, be that CGMCC No.7939 or deposit number are that the Corynebacterium glutamicum of CGMCC No.7940 is inoculated in seed culture medium and expands numerous with deposit number, the culture that then will expand after numerous changes the fermention medium fermentation over to, and keeping pH value between yeast phase is 4-8.
As preferably, the pH value between described yeast phase is 4.9-7.4.
As preferably, described seed culture medium is comprised of 20g/L glucose, 0.5g/L potassium primary phosphate, 1.0g/L dipotassium hydrogen phosphate, 30g/L corn steep liquor, 0.4g/L sal epsom, 5.5g/L urea, and the pH value is 7.0-7.2.
As preferably, described fermention medium is comprised of 160g/L glucose, 40g/L ammonium chloride, 10g/L corn steep liquor, 0.5g/L dipotassium hydrogen phosphate, 0.5g/L potassium primary phosphate, 0.5g/L sal epsom, 50g/L calcium carbonate, 0.005g/L ferrous sulfate, 0.025g/L manganous sulfate, 0.005g/L zinc sulfate, 1.4g/L urea, and the pH value is 7.0-7.2.
The present invention also provides the application of aminoglycoside antibiotics in screening L-glutaminate superior strain.
As preferably, described aminoglycoside antibiotics is Streptomycin sulphate or Liu Suanyan NEOMYCIN SULPHATE.
By above technical scheme as can be known, deposit number of the present invention is the Corynebacterium glutamicum MHZ-0510 of CGMCC No.7939, and ability that its fermentation generates L-glutaminate significantly improves than the wild-type Corynebacterium glutamicum, the L-glutaminate output increased 25.0%.Deposit number of the present invention is that ability that its fermentation of Corynebacterium glutamicum MHZ-0511 of CGMCC No.7940 generates L-glutaminate significantly improves than the wild-type Corynebacterium glutamicum equally, the L-glutaminate output increased 18.75%.Therefore, deposit number of the present invention is that CGMCC No.7939 and deposit number are the production that the Corynebacterium glutamicum of CGMCC No.7940 can be widely used in L-glutaminate.Corynebacterium glutamicum of the present invention is to obtain through the screening of the aminoglycoside antibioticss such as Streptomycin sulphate or Liu Suanyan NEOMYCIN SULPHATE, it has the resistance to aminoglycoside antibioticss such as Streptomycin sulphate or Liu Suanyan NEOMYCIN SULPHATEs, and improved the L-glutaminate synthesis capability, thereby L-glutaminate output is improved.Therefore, aminoglycoside antibiotics can be widely used in the screening of L-glutaminate.
The explanation of biological preservation information
Bacterial strain MHZ-0510: Classification And Nomenclature: Corynebacterium glutamicum, Corynebacterium glutamicum is deposited in China Committee for Culture Collection of Microorganisms common micro-organisms center on July 19th, 2013, the address is No. 3, Yard 1, BeiChen xi Road, Chaoyang District, Beijing City, Institute of Microorganism, Academia Sinica, deposit number is CGMCC No.7939.
Bacterial strain MHZ-0511: Classification And Nomenclature: Corynebacterium glutamicum, Corynebacterium glutamicum is deposited in China Committee for Culture Collection of Microorganisms common micro-organisms center on July 19th, 2013, the address is No. 3, Yard 1, BeiChen xi Road, Chaoyang District, Beijing City, Institute of Microorganism, Academia Sinica, deposit number is CGMCC No.7940.
Embodiment
The embodiment of the invention discloses Corynebacterium glutamicum and application thereof.Those skilled in the art can use for reference this paper content, suitably improve processing parameter and realize.Special needs to be pointed out is that all similarly replace and change apparent to those skilled in the art, they all are deemed to be included in the present invention.Bacterial strain of the present invention is described by preferred embodiment, and the related personnel obviously can change or suitably change and combination product as herein described within not breaking away from content of the present invention, spirit and scope, realizes and use the technology of the present invention.
For realizing purpose of the present invention, the present invention adopts following technical scheme:
The present invention take wild-type Corynebacterium glutamicum B498(available from the Shanghai City Industry Wei Biological Research Institute) as starting strain, take N-methyl-N ＇ nitro-N-nitrosoguanidine as mutagenic compound it is carried out chemomorphosis, then will be coated on respectively on the substratum that contains Streptomycin sulphate or Liu Suanyan NEOMYCIN SULPHATE through the suspension bacteria liquid of the Corynebacterium glutamicum B498 after the mutagenesis.Filter out the bacterial strain with streptomycin resistance from containing the Streptomycin sulphate substratum, called after bacterial strain MHZ-0510.Filter out the bacterial strain with neomycin resistance from containing the Liu Suanyan NEOMYCIN SULPHATE substratum, called after bacterial strain MHZ-0511.
The present invention with the above-mentioned bacterial strain MHZ-0510 that filters out and MHZ-0511 according to the elegant pearl in east, Cai Miaoying chief editor " method of common bacteria system identification handbook is carried out physio-biochemical characteristics to it and is detected, and detected result is consistent with the wild-type Corynebacterium glutamicum.In addition, analyze through the 16S DNA detection, bacterial strain MHZ-0510 and MHZ-0511 and wild-type Corynebacterium glutamicum homology in conjunction with physiological and biochemical property, identify that it is Corynebacterium glutamicum up to 99%.
For above-mentioned Corynebacterium glutamicum, the present patent application people has been deposited in China Committee for Culture Collection of Microorganisms common micro-organisms center on July 19th, 2013, the address is No. 3, Yard 1, BeiChen xi Road, Chaoyang District, Beijing City, Institute of Microorganism, Academia Sinica, wherein, the deposit number of bacterial strain MHZ-0510 is CGMCC No.7939, and the deposit number of bacterial strain MHZ-0511 is CGMCC No.7940.
In an embodiment, the L-glutaminate fermentation simultaneous test of Corynebacterium glutamicum MHZ-0510 of the present invention, MHZ-0511 and wild-type Corynebacterium glutamicum B498 shows, the synthetic L-glutaminate content of Corynebacterium glutamicum MHZ-0510 fermentation of the present invention is 4.0g/L, and the synthetic L-glutaminate content of wild-type Corynebacterium glutamicum B498 fermentation is 3.2g/L, the L-glutaminate output increased 25.0%.The synthetic L-glutaminate content of Corynebacterium glutamicum MHZ-0511 of the present invention fermentation is 3.8g/L, and the synthetic L-glutaminate content of wild-type Corynebacterium glutamicum B498 fermentation is 3.2g/L, the L-glutaminate output increased 18.75%.Show that Corynebacterium glutamicum MHZ-0510 of the present invention and MHZ-0511 can be applied to produce in the L-glutaminate L-glutaminate output increased.Therefore, the invention provides Corynebacterium glutamicum MHZ-0510 and the MHZ-0511 application in producing L-glutaminate, namely deposit number is the Corynebacterium glutamicum of CGMCC No.7939 and the application of Corynebacterium glutamicum in producing L-glutaminate that deposit number is CGMCC No.7940.
In addition, the present invention also provides a kind of L-glutaminate production method, be that CGMCC No.7939 or deposit number are that the Corynebacterium glutamicum of CGMCC No.7940 is inoculated in seed culture medium and expands numerous with deposit number, the culture that then will expand after numerous changes the fermention medium fermentation over to, and keeping pH value between yeast phase is 4-8.
Wherein, as preferably, the pH value between yeast phase is 4.9-7.4.
Production method of the present invention can be performed until and no longer produce till the L-glutaminate, then can separate L-glutaminate according to this area ordinary method.
Fermention medium for the seed culture medium that expands numerous usefulness and fermentation usefulness is known in this field, and those skilled in the art all can adopt suitable medium to carry out the fermentation of L-glutaminate.
As preferably, seed culture medium of the present invention is comprised of 20g/L glucose, 0.5g/L potassium primary phosphate, 1.0g/L dipotassium hydrogen phosphate, 30g/L corn steep liquor, 0.4g/L sal epsom, 5.5g/L urea, and the pH value is 7.0-7.2.
As preferably, fermention medium of the present invention is comprised of 160g/L glucose, 40g/L ammonium chloride, 10g/L corn steep liquor, 0.5g/L dipotassium hydrogen phosphate, 0.5g/L potassium primary phosphate, 0.5g/L sal epsom, 50g/L calcium carbonate, 0.005g/L ferrous sulfate, 0.025g/L manganous sulfate, 0.005g/L zinc sulfate, 1.4g/L urea, and the pH value is 7.0-7.2.
Aminoglycoside antibiotics (Aminoglycosides) is the glycoside microbiotic that is formed by connecting by oxo bridge by aminosugar and aminocyclitol.Have from the Streptomycin sulphate of streptomycete etc., from the natural aminoglycosides such as gentamicin of micromonospora, also have the semi-synthetic aminoglycosides such as amikacin.Aminoglycoside antibiotics mainly is the synthetic of anti-bacteria protein for the effect of bacterium, point of application is at the aminoacyl site of the 16S RNA of cell 30S ribosomal subunit area decoder, it can affect the synthetic whole process of bacterioprotein, hinder the synthetic of initial recombination thing, induce bacterium resultant fault albumen and prevent the release of synthetic proteins, thereby cause bacterium dead.
Streptomycin sulphate and Liu Suanyan NEOMYCIN SULPHATE are aminoglycoside antibioticss, disturb bacterioprotein synthetic on the intracellular rrna by being incorporated into, make it the protein of resulting anomaly, and the bacterial cell membrane permeability is increased, cause in the cell important physiologically substance to leak outside and present germicidal action, stronger to bacterium germicidal action stationary phase, be sterilization stationary phase class microbiotic.
At wild strain after the aminoglycoside antibioticss such as Streptomycin sulphate or Liu Suanyan NEOMYCIN SULPHATE screenings, may be because aminoglycoside antibioticss such as the protein opposing Streptomycin sulphate of described Corynebacterium glutamicum resulting anomaly or Liu Suanyan NEOMYCIN SULPHATEs, these unusual protein cause the L-glutaminate synthetase series to remove the feedback inhibition of some product, thereby cause the L-glutaminate output of mutant strain to be improved, perhaps the glutamine translocator function generation on the described Corynebacterium glutamicum cytolemma changes and has promoted the speed that glutamine is gone out from intracellular transport, thereby causes the L-glutaminate output of mutant strain to be improved.And Corynebacterium glutamicum MHZ-0510 of the present invention and MHZ-0511 obtain through Streptomycin sulphate or Liu Suanyan NEOMYCIN SULPHATE screening, have had the resistance to Streptomycin sulphate or Liu Suanyan NEOMYCIN SULPHATE, and have improved the L-glutaminate synthesis capability.Therefore the present invention also provides the application of aminoglycoside antibiotics in screening L-glutaminate superior strain.
As preferably, described aminoglycoside antibiotics is Streptomycin sulphate or Liu Suanyan NEOMYCIN SULPHATE.
In order further to understand the present invention, the present invention is described in detail below in conjunction with embodiment.
Embodiment 1: the screening of Corynebacterium glutamicum MHZ-0510 of the present invention, MHZ-0511
Starting strain-wild-type Corynebacterium glutamicum B498 is seeded in the LB liquid nutrient medium 30 ℃ cultivates the bacteria suspension that obtained to be in logarithmic phase in 10 hours, then this bacteria suspension is coated on the LB solid plate, an amount of N-methyl-N ＇ nitro-N-nitrosoguanidine solid particulate is put to LB solid plate central authorities, and placing 30 ℃ of incubators to cultivate after 16 hours has the lawn of faint growth to be suspended in an amount of stroke-physiological saline solution around scraping N-methyl-N ＇ nitro-N-nitrosoguanidine particle.The physiological saline that is suspended with lawn is coated on respectively on the LB solid plate that contains 1.0mg/L Streptomycin sulphate or Liu Suanyan NEOMYCIN SULPHATE, 30 ℃ are continued to cultivate 2 days, according to feature picking list bacterium colonies such as colonial morphology, colors, wherein filter out the bacterial strain with streptomycin resistance from containing the Streptomycin sulphate substratum, called after bacterial strain MHZ-0510.Filter out the bacterial strain with neomycin resistance from containing the Liu Suanyan NEOMYCIN SULPHATE substratum, called after bacterial strain MHZ-0511.
LB liquid nutrient medium/LB solid plate prescription is as follows: extractum carnis 5g, peptone 10g, NaCl5g, vitamin H 50 μ g, VitB1 100 μ g, leucine 100mg, homoserine 100mg, Threonine 100mg, methionine(Met) 100mg, agar 18g are settled to 1000mL with dissolved in distilled water and after regulating pH to 6.8-7.4.
Wherein, the difference of LB liquid nutrient medium and LB solid plate is whether agar adds.Vitamin H, VitB1, leucine, homoserine, Threonine, the nonessential interpolation of methionine(Met) can be added according to actual needs.
With above-mentioned bacterial strain MHZ-0510, the MHZ-0511 that filters out according to the elegant pearl in east, Cai Miaoying chief editor " method of common bacteria system identification handbook is carried out physio-biochemical characteristics to it and is detected, and detected result is consistent with the wild-type Corynebacterium glutamicum.In addition, analyze through the 16S DNA detection, bacterial strain MHZ-0510 and MHZ-0511 and wild-type Corynebacterium glutamicum homology in conjunction with physiological and biochemical property, identify that it is Corynebacterium glutamicum up to 99%.
Embodiment 2: L-glutaminate production method of the present invention and L-glutaminate fermentation simultaneous test
1, fermentation process
Corynebacterium glutamicum MHZ-0510 of the present invention and MHZ-0511 are seeded in respectively expand in the seed culture medium of the following stated numerous, in 30 ℃ of shaking culture 16 hours, the gained culture is inoculated in the fermention medium of the following stated, the volume ratio of culture and fermention medium is that 1:10(those skilled in the art can suitably regulate according to the amount of the fermention medium in the actual production, this ratio is preferred proportion), 30 ℃ of shaking culture are to no longer producing (being generally about 72 hours) till the L-glutaminate.In fermention medium during shaking culture, keep pH value in the fermention medium between 6.5-7.4.
Seed culture medium: 20g/L glucose, 0.5g/L potassium primary phosphate, 1.0g/L dipotassium hydrogen phosphate, 30g/L corn steep liquor, 0.4g/L sal epsom, 5.5g/L urea form, and the pH value is 7.0-7.2.
Fermention medium: 160g/L glucose, 40g/L ammonium chloride, 10g/L corn steep liquor, 0.5g/L dipotassium hydrogen phosphate, 0.5g/L potassium primary phosphate, 0.5g/L sal epsom, 50g/L calcium carbonate, 0.005g/L ferrous sulfate, 0.025g/L manganous sulfate, 0.005g/L zinc sulfate, 1.4g/L urea form, and the pH value is 7.0-7.2.
2, L-glutaminate fermentation simultaneous test
Corynebacterium glutamicum MHZ-0510 of the present invention, MHZ-0511 and wild-type Corynebacterium glutamicum B498 are fermented simultaneously according to aforementioned production method, the yeasting of three kinds of bacterial strains, inoculum size are all identical, measure three kinds of L-glutaminate content that bacterial strain synthesized by the bio-sensing instrument after stopping to ferment.
The result shows that wild-type Corynebacterium glutamicum B498 output is 3.2g/L, and Corynebacterium glutamicum MHZ-0510 output of the present invention is 4.0g/L, and its L-glutaminate output has improved 25.0% than starting strain wild-type Corynebacterium glutamicum B498.Corynebacterium glutamicum MHZ-0511 output of the present invention is 3.8g/L, and its L-glutaminate output has improved 18.75% than starting strain wild-type Corynebacterium glutamicum B498.Show that deposit number of the present invention is that the ability that the Corynebacterium glutamicum MHZ-0510 of CGMCC No.7939 and Corynebacterium glutamicum MHZ-0511 that deposit number is CGMCC No.7940 fermentation generate L-glutaminate significantly improves, and can be widely used in the fermentative production of L-glutaminate.
The explanation of above embodiment just is used for helping to understand method of the present invention and core concept thereof.Should be pointed out that for those skilled in the art, under the prerequisite that does not break away from the principle of the invention, can also carry out some improvement and modification to the present invention, these improvement and modification also fall in the protection domain of claim of the present invention.
Claims (10)
1. a Corynebacterium glutamicum is deposited in China Committee for Culture Collection of Microorganisms common micro-organisms center, and deposit number is CGMCC No.7939.
2. deposit number is the application of Corynebacterium glutamicum in producing L-glutaminate of CGMCC No.7939.
3. a Corynebacterium glutamicum is deposited in China Committee for Culture Collection of Microorganisms common micro-organisms center, and deposit number is CGMCC No.7940.
4. deposit number is the application of Corynebacterium glutamicum in producing L-glutaminate of CGMCC No.7940.
5. the production method of a L-glutaminate, it is characterized in that, be that CGMCC No.7939 or deposit number are that the Corynebacterium glutamicum of CGMCC No.7940 is inoculated in seed culture medium and expands numerous with deposit number, the culture that then will expand after numerous changes the fermention medium fermentation over to, and keeping pH value between yeast phase is 4-8.
6. described production method according to claim 5 is characterized in that the pH value between described yeast phase is 4.9-7.4.
7. described production method according to claim 5, it is characterized in that, described seed culture medium is comprised of 20g/L glucose, 0.5g/L potassium primary phosphate, 1.0g/L dipotassium hydrogen phosphate, 30g/L corn steep liquor, 0.4g/L sal epsom, 5.5g/L urea, and the pH value is 7.0-7.2.
8. described production method according to claim 5, it is characterized in that, described fermention medium is comprised of 160g/L glucose, 40g/L ammonium chloride, 10g/L corn steep liquor, 0.5g/L dipotassium hydrogen phosphate, 0.5g/L potassium primary phosphate, 0.5g/L sal epsom, 50g/L calcium carbonate, 0.005g/L ferrous sulfate, 0.025g/L manganous sulfate, 0.005g/L zinc sulfate, 1.4g/L urea, and the pH value is 7.0-7.2.
9. the application of aminoglycoside antibiotics in screening L-glutaminate superior strain.
10. according to claim 9 described application is characterized in that, described aminoglycoside antibiotics is Streptomycin sulphate or Liu Suanyan NEOMYCIN SULPHATE.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310351990.9A CN103374540B (en) | 2013-08-13 | 2013-08-13 | Corynebacterium glutamicum and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310351990.9A CN103374540B (en) | 2013-08-13 | 2013-08-13 | Corynebacterium glutamicum and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103374540A true CN103374540A (en) | 2013-10-30 |
| CN103374540B CN103374540B (en) | 2015-04-22 |
Family
ID=49460373
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310351990.9A Active CN103374540B (en) | 2013-08-13 | 2013-08-13 | Corynebacterium glutamicum and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103374540B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105861361A (en) * | 2016-04-13 | 2016-08-17 | 福建省微生物研究所 | Application of Corynebacterium glutamicum FX69 in purification of piggery wastewater anaerobic effluent |
| CN105950517A (en) * | 2016-06-30 | 2016-09-21 | 江南大学 | Corynebacterium glutamicum and application thereof |
| CN106065411A (en) * | 2016-08-10 | 2016-11-02 | 洛阳华荣生物技术有限公司 | Fermentative Production creatine |
| CN106119181A (en) * | 2016-06-30 | 2016-11-16 | 江南大学 | A kind of genetic engineering bacterium producing poly butyric hydroxyl valerate and application process thereof |
| CN112812985A (en) * | 2020-11-11 | 2021-05-18 | 新疆阜丰生物科技有限公司 | Method for improving fermentation acid production of glutamine |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106148440B (en) * | 2016-08-10 | 2021-12-07 | 洛阳华荣生物技术有限公司 | Production of agmatine by fermentation method |
| CN107227283B (en) * | 2017-05-26 | 2021-01-15 | 廊坊梅花生物技术开发有限公司 | Corynebacterium glutamicum and construction method and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003014330A2 (en) * | 2001-08-06 | 2003-02-20 | Degussa Ag | Coryneform bacteria which produce chemical compounds ii |
| WO2003040373A2 (en) * | 2001-08-06 | 2003-05-15 | Degussa Ag | Production of l-lysine by genetically modified corynebacterium glutamicum strains |
| CN1451047A (en) * | 1999-06-25 | 2003-10-22 | Basf公司 | Corynebacterium glutamicum genes encoding stress resistance and tolerance proteins |
| US6777229B1 (en) * | 1999-11-05 | 2004-08-17 | Degussa Ag | Plasmids from Corynebacterium glutamicum and use thereof |
-
2013
- 2013-08-13 CN CN201310351990.9A patent/CN103374540B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1451047A (en) * | 1999-06-25 | 2003-10-22 | Basf公司 | Corynebacterium glutamicum genes encoding stress resistance and tolerance proteins |
| US6777229B1 (en) * | 1999-11-05 | 2004-08-17 | Degussa Ag | Plasmids from Corynebacterium glutamicum and use thereof |
| WO2003014330A2 (en) * | 2001-08-06 | 2003-02-20 | Degussa Ag | Coryneform bacteria which produce chemical compounds ii |
| WO2003040373A2 (en) * | 2001-08-06 | 2003-05-15 | Degussa Ag | Production of l-lysine by genetically modified corynebacterium glutamicum strains |
| WO2003014330A3 (en) * | 2001-08-06 | 2003-12-18 | Degussa | Coryneform bacteria which produce chemical compounds ii |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105861361A (en) * | 2016-04-13 | 2016-08-17 | 福建省微生物研究所 | Application of Corynebacterium glutamicum FX69 in purification of piggery wastewater anaerobic effluent |
| CN105950517A (en) * | 2016-06-30 | 2016-09-21 | 江南大学 | Corynebacterium glutamicum and application thereof |
| CN106119181A (en) * | 2016-06-30 | 2016-11-16 | 江南大学 | A kind of genetic engineering bacterium producing poly butyric hydroxyl valerate and application process thereof |
| CN105950517B (en) * | 2016-06-30 | 2019-05-17 | 江南大学 | A kind of Corynebacterium glutamicum and its application |
| CN106119181B (en) * | 2016-06-30 | 2019-09-03 | 江南大学 | A kind of genetic engineering bacterium and its application method producing polyhydroxybutyrate hydroxyl valerate |
| CN106065411A (en) * | 2016-08-10 | 2016-11-02 | 洛阳华荣生物技术有限公司 | Fermentative Production creatine |
| CN112812985A (en) * | 2020-11-11 | 2021-05-18 | 新疆阜丰生物科技有限公司 | Method for improving fermentation acid production of glutamine |
| CN112812985B (en) * | 2020-11-11 | 2023-01-10 | 新疆阜丰生物科技有限公司 | Method for improving acid production of glutamine fermentation |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103374540B (en) | 2015-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103374540B (en) | Corynebacterium glutamicum and application thereof | |
| CN101285046B (en) | Mutant strain streptomyces albus TUST2 and process for producing epsilon-polylysine and salts thereof by using the mutant strain | |
| EP3816293B1 (en) | Strains and processes for single cell protein or biomass production | |
| CN110373359A (en) | A kind of streptomyces albus X-18 and the method using bacterium production epsilon-polylysine | |
| US10053744B2 (en) | Yeast strain with high yield of glutathione | |
| WO2012016445A1 (en) | Bacillus subtilis strain and uses thereof | |
| JPS5816872B2 (en) | Corynebacterium glutamicum mutant strain | |
| JP6857041B2 (en) | Carnosine production method and new microorganisms | |
| CN104726381B (en) | Strain for producing L-lysine and method for producing L-lysine by using same | |
| CN1181191C (en) | Microorganism producing 5'-inosinic acid and process for producing 5'-inosinic acid using the same | |
| CN105176859B (en) | The bacterial strain MQO-153 of one plant of production arginine deiminase | |
| CN101323866A (en) | Method for producing L-ornithine by microorganism fermentation | |
| CN116716231B (en) | Escherichia coli and application thereof in fermentation production of tryptophan | |
| CN111778178B (en) | Application of marine streptomyces griseoflavus HN60 in antibacterial aspect | |
| CN111378592A (en) | Bacillus licheniformis and method for treating malodorous organic wastewater by using same to purify water | |
| CN102382787B (en) | Corynebacterium pekinense and application thereof | |
| CN103184180A (en) | Lactobacillus buchneri for producing mannitol, and method for producing mannitol by fermentation | |
| CN102399732B (en) | Beijing corynebacterium and application thereof | |
| CN103146797B (en) | Compound biological flocculant and preparation method thereof | |
| JP2019198296A (en) | Method for producing tropolones | |
| CN117229980B (en) | Weissella sinica fermented feed and application and deodorization effect thereof | |
| JPS61177993A (en) | Production of l-isoleucine | |
| CN105176954B (en) | A kind of method that arginine deiminase is prepared using bacterial strain MQO-153 | |
| KR930001389B1 (en) | Process for producing l-arginine | |
| CN105018453A (en) | Method for preparation of arginase from strain MQO-154 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |